Tuesday

19th Mar 2019

Opinion

Intellectual property protection - the cure for Europe's ills

  • The Commission risks giving a 'sweetheart' deal for generic drug companies - which does nothing for research and development (Photo: www.freeimages.co.uk)

Like it or not, Europe is getting older, thanks to a combination of falling birthrates and increasing lifespans: from 2006 to 2016, the proportion of European Union citizens aged 65 and up increased from 16.8 percent to 19.2 percent, while the share of under-15s slipped from 16 percent to 15.6 percent.

By 2080, three in ten Europeans will be 65 or older.

Read and decide

Join EUobserver today

Support quality EU news

Get instant access to all articles — and 18 year's of archives. 30 days free trial.

... or join as a group

Our ageing population isn't a bad thing.

Most people would probably agree it's good to live longer, while smaller family sizes are associated with a higher standard of living and social mobility.

Nevertheless, it presents a looming health challenge in the form of more serious and chronic diseases, including cancer, diabetes, hypertension, and dementia.

Chronic diseases already account for the lion's share of health expenditures, at four-fifths of the European total, in addition to costing an estimated €115bn per year in lost productivity from deaths among working adults.

So it is puzzling to see Europe's governing bodies considering measures that would undermine the incentives for scientific innovation needed to treat these illnesses, along with countless other future remedies – all in the name of marginal cost savings that can undoubtedly be found elsewhere.

For almost two decades, Europe has used a system of intellectual property protections and incentives to encourage research into treatments for a range of diseases, for example by guaranteeing longer market exclusivity for drugs to treat rare conditions, or granting extended patent protection that partially compensates innovators for the long regulatory approval process involved in bringing a new medicine to market.

The system works

Thanks to R&D incentives, the number of new treatments for rare diseases approved by the European Medicines Agency under the program soared from just eight in 2000 to 136 today.

But protections are needed now more than ever. Over the years, the science of new medicines development has become more difficult, and the scope, complexity and cost of conducting clinical trials has increased dramatically.

However with national budgets under pressure and healthcare costs increasing, in June 2016 the European Commission began considering the possibility of rolling back medical research incentives, on the faulty assumption they are somehow driving higher drug prices.

But not only is that premise flawed – the proposed fix will do nothing to benefit ordinary health consumers.

In fact, Europe is not spending dramatically more on drugs, and only modest increases are forecast in coming years.

According to the World Health Organization, retail expenditures on medicines in the EU-15 decreased steadily as a proportion of total healthcare spending from 2004 to 2014, while per capita expenditures on drugs remained stable.

Looking to the future, European drug spending is predicted to grow at a compound annual rate of just one percent to four percent from 2016-2021, roughly in line with the predicated rate of inflation for Europe over the same period.

As these numbers indicate, drug costs have not played a significant role in rising overall healthcare expenditures, which grew from an average of 8.8 percent of GDP to 9.9 percent across the EU from 2005-2015.

Rather, increasing healthcare costs are largely the result – in Europe as in the rest of the developed world – of growing demand for long-term care (expected to double to 3.6 percent of GDP by 2060), as well as new technology and stagnant productivity.

The researchers who discover and develop new treatments and cures may be easy political targets.

Drug prices aren't the problem

But since drug prices aren't actually the problem, it's worth asking what's really behind the move to weaken incentives.

The answer might lie with a proposal to limit extended protections Europe provides for some medicines. According to the European Commission's own background paper, the proposal is intended to enable generic drug makers on the continent to begin selling copies of these medicines overseas during the period of extended protection.

This might be a sweetheart deal for generic drug companies – which spend virtually nothing on R&D for new drugs. But it would do nothing for European patients or national health systems, while putting the kind of R&D jobs the EU needs more of at risk across the continent.

The European commission should recalibrate its approach. We should strive to encourage innovation, not undermine it. Our market-based system has yielded practically all medical advances to date, and with an ageing population beset by chronic disease, we urgently need better treatments and cures.

Pietro Paganini is president of Italian think tank Competere, serves as an adjunct professor at John Cabot University in Rome and Fox School of Business at Temple University of Philadelphia, and a columnist for the Italian daily newspaper, La Stampa.

Why are our medicines so expensive?

The EU should be promoting open innovation in upcoming trade talks with India and should work to bring down the prices of essential medicines, both abroad and within its borders.

Catalan independence trial is widening Spain's divides

What is really needed is not the theatre of a rebellion trial, but a forensic examination of whether public funds were misused, and a process of dialogue and negotiation on how the Catalan peoples' right to self-determination can be satisfied.

My plan for defending rule of law in EU

EPP leader and prospective next EU Commission president Manfred Weber spells out his plan for dealing with recalcitrant EU member states - ahead of Wednesday's EPP meeting on the vexed issue of Hungary's Viktor Orban and Fidesz.

News in Brief

  1. Violent 'yellow vest' protesters ban in Paris
  2. Russia celebrates fifth anniversary of Crimea annexation
  3. Blow for May as third vote on Brexit deal ruled out
  4. Three killed in possible 'terror' gun attack in Utrecht
  5. Third Brexit vote this week only if DUP will support it
  6. Germany's two largest banks confirm merger talks
  7. Serbian pro-democracy protests reach 15th week
  8. 'Yellow Vest' riots leave Paris shops vandalised

Italy should capitalise on Brexit

Now that the UK is leaving, Italy can, and should, step up. It is the third largest country and economy in the EU. Spain and Poland follow, but they are significantly smaller economically and population-wise.

The Magnitsky Act - and its name

It is disappointing that so many MEPs in the Socialist and Green group caved in to Russian interests, in fear of challenging a plutocratic regime, by saying 'no' to naming the Magnitsky legislation by its rightful name: Magnitsky.

Stakeholders' Highlights

  1. Nordic Council of MinistersNew Secretary General: Nordic co-operation must benefit everybody
  2. Platform for Peace and JusticeMEP Kati Piri: “Our red line on Turkey has been crossed”
  3. UNICEF2018 deadliest year yet for children in Syria as war enters 9th year
  4. Nordic Council of MinistersNordic commitment to driving global gender equality
  5. International Partnership for Human RightsMeet your defender: Rasul Jafarov leading human rights defender from Azerbaijan
  6. UNICEFUNICEF Hosts MEPs in Jordan Ahead of Brussels Conference on the Future of Syria
  7. Nordic Council of MinistersNordic talks on parental leave at the UN
  8. International Partnership for Human RightsTrial of Chechen prisoner of conscience and human rights activist Oyub Titiev continues.
  9. Nordic Council of MinistersNordic food policy inspires India to be a sustainable superpower
  10. Nordic Council of MinistersMilestone for Nordic-Baltic e-ID
  11. Counter BalanceEU bank urged to free itself from fossil fuels and take climate leadership
  12. Intercultural Dialogue PlatformRoundtable: Muslim Heresy and the Politics of Human Rights, Dr. Matthew J. Nelson

Stakeholders' Highlights

  1. Platform for Peace and JusticeTurkey suffering from the lack of the rule of law
  2. UNESDASoft Drinks Europe welcomes Tim Brett as its new president
  3. Nordic Council of MinistersNordic ministers take the lead in combatting climate change
  4. Counter BalanceEuropean Parliament takes incoherent steps on climate in future EU investments
  5. International Partnership For Human RightsKyrgyz authorities have to immediately release human rights defender Azimjon Askarov
  6. Nordic Council of MinistersSeminar on disability and user involvement
  7. Nordic Council of MinistersInternational appetite for Nordic food policies
  8. Nordic Council of MinistersNew Nordic Innovation House in Hong Kong
  9. Nordic Council of MinistersNordic Region has chance to become world leader when it comes to start-ups
  10. Nordic Council of MinistersTheresa May: “We will not be turning our backs on the Nordic region”
  11. International Partnership for Human RightsOpen letter to Emmanuel Macron ahead of Uzbek president's visit
  12. International Partnership for Human RightsRaising key human rights concerns during visit of Turkmenistan's foreign minister

Join EUobserver

Support quality EU news

Join us